Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Monday announced the the re availability of Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg following approval by the US Food and Drug Administration (USFDA) to treat severe acne as well as prevent certain skin cancers.

The Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg is reportedly the therapeutic equivalent generic version of Accutane and is being launched under an approved Risk Evaluation and Mitigation Strategy (REMS) Programme as well as the US FDA's special restricted iPLEDGE distribution programme.

For the most recent 12 months ending in March 2019, the company's Zenatane (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately USD525m MAT, according to IQVIA Health.

In addition, the company's Zenatane (Isotretinoin Capsules, USP) are available in 3x10 (30-count) blister packages of 10 mg, 20 mg 30 mg, and 40 mg Capsules, USP.